Cargando…
Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770808/ https://www.ncbi.nlm.nih.gov/pubmed/35070977 http://dx.doi.org/10.3389/fonc.2021.773394 |
_version_ | 1784635449986252800 |
---|---|
author | Fan, Shuang Shen, Meng-Zhu Zhang, Xiao-Hui Xu, Lan-Ping Wang, Yu Yan, Chen-Hua Chen, Huan Chen, Yu-Hong Han, Wei Wang, Feng-Rong Wang, Jing-Zhi Zhao, Xiao-Su Qin, Ya-Zhen Chang, Ying-Jun Liu, Kai-Yan Huang, Xiao-Jun Mo, Xiao-Dong |
author_facet | Fan, Shuang Shen, Meng-Zhu Zhang, Xiao-Hui Xu, Lan-Ping Wang, Yu Yan, Chen-Hua Chen, Huan Chen, Yu-Hong Han, Wei Wang, Feng-Rong Wang, Jing-Zhi Zhao, Xiao-Su Qin, Ya-Zhen Chang, Ying-Jun Liu, Kai-Yan Huang, Xiao-Jun Mo, Xiao-Dong |
author_sort | Fan, Shuang |
collection | PubMed |
description | In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN)-α therapy and donor lymphocyte infusion (DLI) in patients with t(8;21) AML following allo-HSCT. We also evaluated the appropriate method for patients with different levels of RUNX1-RUNX1T1 transcripts. In this retrospective study, consecutive patients who had high-risk t(8;21) AML and received allo-HSCT were enrolled. The inclusion criteria were as follows: (1) age ≤65 years; (2) regained MRD positive following allo-HSCT. MRD positive was defined as the loss of a ≥4.5-log reduction and/or <4.5-log reduction in the RUNX1-RUNX1T1 transcripts, and high-level, intermediate-level, and low-level MRDs were, respectively, defined as <2.5-log, 2.5−3.5-log, and 3.5−4.5-log reductions in the transcripts compared with the pretreatment baseline level. Patients with positive RUNX1-RUNX1T1 could receive preemptive IFN-α therapy or DLI, which was primarily based on donor availability and the intentions of physicians and patients. The patients received recombinant human IFN-α-2b therapy by subcutaneous injection twice a week every 4 weeks. IFN-α therapy was scheduled for six cycles or until the RUNX1-RUNX1T1 transcripts were negative for at least two consecutive tests. The rates of MRD turning negative for patients with low-level, intermediate-level, and high-level RUNX1-RUNX1T1 receiving IFN-α were 87.5%, 58.1%, and 22.2%, respectively; meanwhile, for patients with intermediate-level and high-level RUNX1-RUNX1T1 receiving DLI, the rates were 50.0% and 14.3%, respectively. For patients with low-level and intermediate-level RUNX1-RUNX1T1, the probability of overall survival at 2 years was higher in the IFN-α group than in the DLI group (87.6% vs. 55.6%; p = 0.003). For patients with high levels of RUNX1-RUNX1T1, the probability of overall survival was comparable between the IFN-α and DLI groups (53.3% vs. 83.3%; p = 0.780). Therefore, patients with low-level and intermediate-level RUNX1-RUNX1T1 could benefit more from preemptive IFN-α therapy compared with DLI. Clinical outcomes were comparable between preemptive IFN-α therapy and DLI in patients with high-level RUNX1-RUNX1T1; however, they should be further improved. |
format | Online Article Text |
id | pubmed-8770808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87708082022-01-21 Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Fan, Shuang Shen, Meng-Zhu Zhang, Xiao-Hui Xu, Lan-Ping Wang, Yu Yan, Chen-Hua Chen, Huan Chen, Yu-Hong Han, Wei Wang, Feng-Rong Wang, Jing-Zhi Zhao, Xiao-Su Qin, Ya-Zhen Chang, Ying-Jun Liu, Kai-Yan Huang, Xiao-Jun Mo, Xiao-Dong Front Oncol Oncology In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN)-α therapy and donor lymphocyte infusion (DLI) in patients with t(8;21) AML following allo-HSCT. We also evaluated the appropriate method for patients with different levels of RUNX1-RUNX1T1 transcripts. In this retrospective study, consecutive patients who had high-risk t(8;21) AML and received allo-HSCT were enrolled. The inclusion criteria were as follows: (1) age ≤65 years; (2) regained MRD positive following allo-HSCT. MRD positive was defined as the loss of a ≥4.5-log reduction and/or <4.5-log reduction in the RUNX1-RUNX1T1 transcripts, and high-level, intermediate-level, and low-level MRDs were, respectively, defined as <2.5-log, 2.5−3.5-log, and 3.5−4.5-log reductions in the transcripts compared with the pretreatment baseline level. Patients with positive RUNX1-RUNX1T1 could receive preemptive IFN-α therapy or DLI, which was primarily based on donor availability and the intentions of physicians and patients. The patients received recombinant human IFN-α-2b therapy by subcutaneous injection twice a week every 4 weeks. IFN-α therapy was scheduled for six cycles or until the RUNX1-RUNX1T1 transcripts were negative for at least two consecutive tests. The rates of MRD turning negative for patients with low-level, intermediate-level, and high-level RUNX1-RUNX1T1 receiving IFN-α were 87.5%, 58.1%, and 22.2%, respectively; meanwhile, for patients with intermediate-level and high-level RUNX1-RUNX1T1 receiving DLI, the rates were 50.0% and 14.3%, respectively. For patients with low-level and intermediate-level RUNX1-RUNX1T1, the probability of overall survival at 2 years was higher in the IFN-α group than in the DLI group (87.6% vs. 55.6%; p = 0.003). For patients with high levels of RUNX1-RUNX1T1, the probability of overall survival was comparable between the IFN-α and DLI groups (53.3% vs. 83.3%; p = 0.780). Therefore, patients with low-level and intermediate-level RUNX1-RUNX1T1 could benefit more from preemptive IFN-α therapy compared with DLI. Clinical outcomes were comparable between preemptive IFN-α therapy and DLI in patients with high-level RUNX1-RUNX1T1; however, they should be further improved. Frontiers Media S.A. 2022-01-06 /pmc/articles/PMC8770808/ /pubmed/35070977 http://dx.doi.org/10.3389/fonc.2021.773394 Text en Copyright © 2022 Fan, Shen, Zhang, Xu, Wang, Yan, Chen, Chen, Han, Wang, Wang, Zhao, Qin, Chang, Liu, Huang and Mo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Fan, Shuang Shen, Meng-Zhu Zhang, Xiao-Hui Xu, Lan-Ping Wang, Yu Yan, Chen-Hua Chen, Huan Chen, Yu-Hong Han, Wei Wang, Feng-Rong Wang, Jing-Zhi Zhao, Xiao-Su Qin, Ya-Zhen Chang, Ying-Jun Liu, Kai-Yan Huang, Xiao-Jun Mo, Xiao-Dong Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title_full | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title_fullStr | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title_short | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation |
title_sort | preemptive immunotherapy for minimal residual disease in patients with t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770808/ https://www.ncbi.nlm.nih.gov/pubmed/35070977 http://dx.doi.org/10.3389/fonc.2021.773394 |
work_keys_str_mv | AT fanshuang preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT shenmengzhu preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT zhangxiaohui preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT xulanping preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT wangyu preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT yanchenhua preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT chenhuan preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT chenyuhong preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT hanwei preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT wangfengrong preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT wangjingzhi preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT zhaoxiaosu preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT qinyazhen preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT changyingjun preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT liukaiyan preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT huangxiaojun preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation AT moxiaodong preemptiveimmunotherapyforminimalresidualdiseaseinpatientswitht821acutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation |